JP7128195B2 - 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 - Google Patents

細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 Download PDF

Info

Publication number
JP7128195B2
JP7128195B2 JP2019546144A JP2019546144A JP7128195B2 JP 7128195 B2 JP7128195 B2 JP 7128195B2 JP 2019546144 A JP2019546144 A JP 2019546144A JP 2019546144 A JP2019546144 A JP 2019546144A JP 7128195 B2 JP7128195 B2 JP 7128195B2
Authority
JP
Japan
Prior art keywords
chimeric protein
ox40l
cells
cd40l
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019546144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508329A5 (https=
JP2020508329A (ja
Inventor
シュライバー，テイラー
フロム，ジョージ
シルヴァ，サレシュ デ
Original Assignee
シャタック ラボ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャタック ラボ，インコーポレイテッド filed Critical シャタック ラボ，インコーポレイテッド
Publication of JP2020508329A publication Critical patent/JP2020508329A/ja
Publication of JP2020508329A5 publication Critical patent/JP2020508329A5/ja
Priority to JP2022130749A priority Critical patent/JP2022159510A/ja
Application granted granted Critical
Publication of JP7128195B2 publication Critical patent/JP7128195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019546144A 2017-02-27 2018-02-27 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 Active JP7128195B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022130749A JP2022159510A (ja) 2017-02-27 2022-08-18 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762464002P 2017-02-27 2017-02-27
US62/464,002 2017-02-27
PCT/US2018/020040 WO2018157165A1 (en) 2017-02-27 2018-02-27 Methods of making and using extracellular domain-based chimeric proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022130749A Division JP2022159510A (ja) 2017-02-27 2022-08-18 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法

Publications (3)

Publication Number Publication Date
JP2020508329A JP2020508329A (ja) 2020-03-19
JP2020508329A5 JP2020508329A5 (https=) 2021-04-08
JP7128195B2 true JP7128195B2 (ja) 2022-08-30

Family

ID=63253416

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019546144A Active JP7128195B2 (ja) 2017-02-27 2018-02-27 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
JP2019546149A Active JP7260477B2 (ja) 2017-02-27 2018-02-27 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP2022130749A Pending JP2022159510A (ja) 2017-02-27 2022-08-18 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
JP2023062366A Active JP7620045B2 (ja) 2017-02-27 2023-04-06 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP2025003769A Withdrawn JP2025061180A (ja) 2017-02-27 2025-01-09 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019546149A Active JP7260477B2 (ja) 2017-02-27 2018-02-27 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP2022130749A Pending JP2022159510A (ja) 2017-02-27 2022-08-18 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
JP2023062366A Active JP7620045B2 (ja) 2017-02-27 2023-04-06 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP2025003769A Withdrawn JP2025061180A (ja) 2017-02-27 2025-01-09 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質

Country Status (15)

Country Link
US (8) US20190367579A1 (https=)
EP (2) EP3585418A4 (https=)
JP (5) JP7128195B2 (https=)
KR (1) KR102745835B1 (https=)
CN (3) CN118994414A (https=)
AU (2) AU2018223821B2 (https=)
BR (1) BR112019017298A2 (https=)
CA (2) CA3054133A1 (https=)
IL (2) IL268198B2 (https=)
MX (1) MX2019009812A (https=)
MY (1) MY207687A (https=)
PH (1) PH12019501533A1 (https=)
SG (1) SG11201906465YA (https=)
WO (2) WO2018157162A1 (https=)
ZA (1) ZA201905488B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022159510A (ja) * 2017-02-27 2022-10-17 シャタック ラボ，インコーポレイテッド 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
CN112566650A (zh) * 2018-06-21 2021-03-26 沙塔克实验室有限公司 异二聚体蛋白及其用途
US20210179689A1 (en) * 2018-08-29 2021-06-17 Shattuck Labs, Inc. Combination therapies comprising tim-3-based chimeric proteins
JP2022512541A (ja) 2018-08-29 2022-02-07 シャタック ラボ，インコーポレイテッド Ｐｄ－１系キメラタンパク質を含む併用療法
EP3844177A4 (en) * 2018-08-29 2022-08-10 Shattuck Labs, Inc. COMBINATION THERAPIES
CN120383683A (zh) * 2018-08-31 2025-07-29 耶鲁大学 Enpp1多肽及其使用方法
CA3112788A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
EP4079750A3 (en) 2018-11-21 2023-01-04 Mayo Foundation for Medical Education and Research Adenoviruses and methods for using adenoviruses
EP3930851A4 (en) * 2019-02-28 2023-03-29 Shattuck Labs, Inc. COMBINATION THERAPIES
CN113710694A (zh) * 2019-04-29 2021-11-26 梅奥医学教育及研究基金会 用于治疗癌症的多价pd-l1结合化合物
CN112111437B (zh) * 2020-05-25 2023-09-05 江南大学 2’-岩藻糖基乳糖产量提高的重组枯草芽孢杆菌及其构建方法
MX2022015157A (es) * 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
KR20230024368A (ko) 2020-06-18 2023-02-20 제넨테크, 인크. 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
CN111808800B (zh) * 2020-07-20 2022-08-26 中南大学湘雅二医院 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用
JP2023541996A (ja) * 2020-09-17 2023-10-04 シャタック ラボ，インコーポレイテッド ＳＩＲＰ１αキメラタンパク質の臨床投与
EP4237000A4 (en) * 2020-11-02 2024-09-18 Athae Bio, Inc. TWO-DOMAIN MULTIMERIC FUSION PROTEINS
AU2021390545A1 (en) * 2020-12-03 2023-07-06 Shattuck Labs, Inc. Methods of treating cancer using tigit-and light-based chimeric proteins
CN116897202A (zh) * 2021-02-24 2023-10-17 科济生物医药（上海）有限公司 Tigit工程化细胞及其组合物
CN115260312B (zh) * 2021-04-30 2025-02-14 保诺科技（北京）有限公司 结合ox40的抗体或抗原结合片段
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CN115960247A (zh) * 2021-10-13 2023-04-14 苏州科锐迈德生物医药科技有限公司 基于t7rna聚合酶的融合多肽及其制备方法、用途
EP4426725A2 (en) * 2021-11-01 2024-09-11 Shattuck Labs, Inc. Chimeric proteins for treating cutaneous inflammation
CN114209815B (zh) * 2021-11-22 2024-04-26 山东大学 一种药物组合物及其制备方法和应用
WO2023105281A1 (en) * 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
CN115490771B (zh) * 2021-12-24 2026-04-28 合肥天港免疫药物有限公司 重组抗体及其应用
CN114196691B (zh) * 2021-12-28 2023-08-11 重庆澳龙生物制品有限公司 一种制备防治牛、羊棘球蚴病多表位重组疫苗的基因、蛋白质、疫苗和应用
KR20250022049A (ko) 2022-06-07 2025-02-14 제넨테크, 인크. 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
CN117624375A (zh) * 2022-08-30 2024-03-01 北京卡替医疗技术有限公司 增强受体、表达增强受体的免疫细胞及其用途
CN116350748A (zh) * 2022-11-01 2023-06-30 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Tigit融合蛋白在制备用于治疗系统性红斑狼疮药物中的应用
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN116041542B (zh) * 2022-12-06 2026-02-17 上海恩凯细胞技术有限公司 逆转肿瘤微环境抑制性信号的nk细胞制备方法及应用
CN116037072B (zh) * 2023-02-24 2025-01-03 宁夏医科大学 一种血清抗体亲和分离材料的制备方法与应用
CN116925236B (zh) * 2023-05-12 2024-06-04 上海恩凯细胞技术有限公司 嵌合转换受体及其应用
AU2024314312A1 (en) * 2023-06-22 2025-10-30 Fbd Biologics Limited Multi-targeting protein complex and methods of use thereof
CN116982600B (zh) * 2023-09-14 2025-11-18 江苏集萃药康生物科技股份有限公司 一种cd69人源化小鼠模型的构建方法及其应用
CN119930791A (zh) * 2023-11-02 2025-05-06 重庆精准生物技术有限公司 特异性tigit肽段
WO2025140345A1 (zh) * 2023-12-29 2025-07-03 沈阳三生制药有限责任公司 一种tigit多肽及tigit/ctla4融合蛋白

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013000234A1 (en) 2011-06-28 2013-01-03 Huabo Biopharm Co., Ltd A novel recomnimant bifunctional fusion protein and its preparation and use
JP2013521311A (ja) 2010-03-05 2013-06-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ES2198025T3 (es) 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
IL150571A0 (en) 2000-01-03 2003-02-12 Tr Associates L L C Novel chimeric proteins and methods for using the same
US20110041190A1 (en) 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
US7696168B2 (en) * 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CA2541006C (en) 2003-10-03 2015-02-17 Brigham And Women's Hospital Tim-3 polypeptides
ES2383300T3 (es) 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
JP2009537145A (ja) 2006-05-15 2009-10-29 バイラル ロジック システムズ テクノロジー コーポレーション 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
US20110028688A1 (en) 2006-06-21 2011-02-03 Genentech, Inc. Crystal structure of ox40l and ox40l complexed with ox40 receptor
WO2008061377A1 (en) 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
EP2160200B1 (en) 2007-05-14 2013-07-10 The University of Chicago Antibody-LIGHT fusion products as cancer therapeutics
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
WO2009114110A1 (en) 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CA2729351C (en) 2008-06-30 2017-01-24 University Of Pennsylvania Fn14/trail fusion proteins
NZ590667A (en) 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
ES2538122T3 (es) 2008-07-21 2015-06-17 Apogenix Gmbh Moléculas de una sola cadena de TNFSF
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
WO2010070047A1 (en) 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
CA2755198A1 (en) 2009-03-13 2010-09-16 Mark L. Tykocinski Ox40/trail fusion proteins
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
CN107090029B (zh) 2010-11-11 2021-07-13 港大科桥有限公司 可溶性 pd-1变体、融合构建体及其用途
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US10179164B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
WO2013119202A1 (en) 2012-02-06 2013-08-15 Providence Health & Services - Oregon Cancer treatment and monitoring methods using ox40 agonists
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
PT2850106T (pt) 2012-05-18 2022-07-18 Aptevo Res & Development Llc Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
PL3575326T3 (pl) 2012-12-17 2022-07-11 Pf Argentum Ip Holdings Llc Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc
WO2014106839A1 (en) * 2013-01-01 2014-07-10 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
WO2014121093A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
WO2014121085A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
CN113684185A (zh) 2013-02-26 2021-11-23 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
CA2902830C (en) 2013-03-12 2023-09-19 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
EP3094651B1 (en) 2014-01-14 2020-03-11 Kymab Limited Anti-light antibodies
CA2936244A1 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
JP6355032B2 (ja) 2014-03-24 2018-07-11 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド 新規組換え二機能性融合タンパク質、それらの調製および使用
EP3148573A4 (en) 2014-05-29 2017-11-15 Medimmune, LLC Ox40l fusion proteins and uses thereof
EP3160497A4 (en) 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
PL3180363T3 (pl) 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CA2969730A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
WO2016112983A1 (en) * 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
SG11201705844SA (en) 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
CN114425077A (zh) 2015-05-18 2022-05-03 起源生物医药公司 Sirp多肽组合物和使用方法
JP6981973B2 (ja) * 2015-10-01 2021-12-17 ヒート バイオロジクス，インコーポレイテッド Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
US20190367579A1 (en) * 2017-02-27 2019-12-05 Shattuck Labs, Inc. Tigit- and light-based chimeric proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521311A (ja) 2010-03-05 2013-06-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
WO2013000234A1 (en) 2011-06-28 2013-01-03 Huabo Biopharm Co., Ltd A novel recomnimant bifunctional fusion protein and its preparation and use
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Nature Medicine，2016年，22，1402-1410
Nature Reviews Clinical Oncology，2016年，13，143-158
Nature Reviews Drug Discovery，2015年，14，561-584

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022159510A (ja) * 2017-02-27 2022-10-17 シャタック ラボ，インコーポレイテッド 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法

Also Published As

Publication number Publication date
JP2022159510A (ja) 2022-10-17
US12071465B2 (en) 2024-08-27
US20240190939A1 (en) 2024-06-13
US20220315637A1 (en) 2022-10-06
ZA201905488B (en) 2024-02-28
JP2020508068A (ja) 2020-03-19
US10899817B2 (en) 2021-01-26
IL313003A (en) 2024-07-01
IL268198B2 (en) 2024-10-01
IL268198A (en) 2019-09-26
JP2023076695A (ja) 2023-06-01
JP2020508329A (ja) 2020-03-19
PH12019501533A1 (en) 2020-02-24
SG11201906465YA (en) 2019-08-27
BR112019017298A2 (pt) 2020-04-14
US20200222503A1 (en) 2020-07-16
CA3054127A1 (en) 2018-08-30
US20220227831A1 (en) 2022-07-21
CA3054133A1 (en) 2018-03-30
EP3585425A4 (en) 2020-10-28
EP3585418A4 (en) 2020-11-25
US20240368242A1 (en) 2024-11-07
KR20190122667A (ko) 2019-10-30
MX2019009812A (es) 2019-10-14
KR102745835B1 (ko) 2024-12-24
RU2019125682A (ru) 2021-03-29
AU2022218575A1 (en) 2022-11-10
WO2018157162A1 (en) 2018-08-30
JP7260477B2 (ja) 2023-04-18
US20200399342A1 (en) 2020-12-24
US20190367579A1 (en) 2019-12-05
RU2019125682A3 (https=) 2021-12-03
MY207687A (en) 2025-03-12
EP3585425A1 (en) 2020-01-01
IL268198B1 (en) 2024-06-01
CN110381983A (zh) 2019-10-25
JP2025061180A (ja) 2025-04-10
US20200283496A1 (en) 2020-09-10
AU2018223821A1 (en) 2019-07-11
CN110381983B (zh) 2024-07-09
JP7620045B2 (ja) 2025-01-22
CN110234345A (zh) 2019-09-13
EP3585418A1 (en) 2020-01-01
US10927159B2 (en) 2021-02-23
CN118994414A (zh) 2024-11-22
WO2018157165A1 (en) 2018-08-30
AU2018223821B2 (en) 2022-05-19
US11332509B2 (en) 2022-05-17

Similar Documents

Publication Publication Date Title
JP7128195B2 (ja) 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
CN108350055B (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
JP2023071979A (ja) Ｖｓｉｇ８ベースのキメラタンパク質
RU2775490C2 (ru) Химерные белки на основе tigit и light
HK40101388A (en) Vsig8-based chimeric proteins
HK40091905A (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
HK40092182A (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191023

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191129

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220719

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220818

R150 Certificate of patent or registration of utility model

Ref document number: 7128195

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150